Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GLP-1 drugs like Ozempic may have health benefits, but they come with risks
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, are among the most common adverse effects.
Huge Study Finds Constellation of Health Benefits for Ozempic Beyond Weight Loss
In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss.
Study ties Ozempic-like drugs to dozens of benefits and risks
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to increase the risk of many others.
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Major study of weight-loss jabs shows slew of benefits but also risks
The risk of heart attack and stroke declines, but gastrointestinal problems and joint inflammation increase: New research has shed more light on the pros and cons of weight-loss jabs.
Researchers reveal benefits, risks linked to popular weight-loss drugs
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,
19m
GLP-1 Users Are Spending Way Less on Groceries and Fast Food, According to a New Study
Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.
13h
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
1d
on MSN
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...
2d
on MSN
Scientists find Ozempic may treat cancer, Alzheimer's and more. Is it hype or truly a "wonder drug?"
Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...
1d
on MSN
Why You Should Eat Every 4 Hours, According to a Gastroenterologist
Dr. Will Bulsiewicz explains the importance of spacing meals apart to improve gut health, enhance digestion, and align with natural body rhythms.
Hosted on MSN
1d
Allurion shares soar 77% after sharing plans for GLP-1RA combo trial
Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.
Medscape
2d
A Guide for Discussing GLP-1s as Obesity Treatments
The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...
3d
on MSN
Ozempic’s health benefits keep growing, but are the risks worth it?
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
2d
on MSN
Oprah Winfrey Gets Mixed Reaction When Sharing Thoughts About “Thin People” on Podcast
Oprah Winfrey is sparking a debate around weight, willpower and perception after the media mogul revealed her perceptions ...
4d
Websites selling compounded GLP-1 RAs often misinform consumers, research reveals
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback